NCT02945215 - A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients | Biotech Hunter

Enrollment

181

Participants

Timeline

Start Date

December 13, 2016

Primary Completion Date

March 21, 2019

Study Completion Date

October 16, 2019

Conditions

B-Cell Lymphoma

Interventions

DRUG

IBI301

IBI301 375mg/㎡

DRUG

Rituximab

Rituximab 375mg/㎡

Trial Locations (12)

Beijing cancer hospital, Beijing

Peking University third hospital, Beijing

The 307th Hospital of Military Medical Sciences, Beijing

Harbin Medical University Cancer Hospital, Haerbin

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

The Third Xiangya Hospital of Central South University, Changsha

Xiangya Hospital of Central South University, Changsha

Jiangsu province people's hospital, Nanjing

West China Hospital,Sichuan University, Chengdu

Tianjin People's Hospital, Tianjin

The First Affiliated Hospital Zhejiang University, Hangzhou

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY